Keyphrases
Childhood Cancer Survivors
73%
Childhood Cancer
69%
Anthracyclines
68%
Cardiotoxicity
33%
Late Effects
32%
Randomized Controlled Trial
30%
High-risk Neuroblastoma
30%
Heart Failure
26%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
24%
Anthracycline-induced Cardiotoxicity
24%
Risk Factors
24%
Confidence Interval
24%
Older Adults
22%
High-dose Chemotherapy
22%
Children with Cancer
19%
Survivors
17%
Cancer Guidelines
17%
Dutch
17%
Overall Survival
15%
Ewing Sarcoma
15%
Event-free Survival
14%
High Risk
14%
Cochrane Review
14%
Preadolescent children
14%
Pediatric Oncology
13%
Cardiac Dysfunction
12%
Echocardiography
11%
MEDLINE
11%
Cancer Patients
10%
Adult Cancer
10%
Embase
10%
Risk of Bias
10%
Infusion Duration
10%
Hazard Ratio
10%
Dexrazoxane
10%
Chemotherapy
10%
Review Authors
9%
Radiotherapy
9%
Treatment Group
9%
Adverse Effects
9%
Cumulative Incidence
9%
Neuroblastoma
9%
In Cancer
9%
Cardiac Function
8%
Hearing Impairment
8%
Antineoplastic Drugs
8%
Long-term Survivors
8%
Cochrane
8%
Young Adult Cancer Survivors
8%
Cardiac Events
8%
Medicine and Dentistry
Childhood Cancer
100%
Ganglioneuroblastoma
35%
Anthracycline
35%
Systematic Review
28%
Malignant Neoplasm
21%
Late Effect
20%
Randomized Controlled Trial
20%
High Dose Chemotherapy
19%
Adverse Event
16%
Radiation Therapy
14%
Cardiotoxicity
14%
Ewing Sarcoma
12%
Overall Survival
12%
Heart Failure
12%
Event Free Survival
11%
Autologous Hematopoietic Stem Cell Transplantation
10%
Cancer in Young Adults
10%
Neoplasm
9%
Disease
9%
Cohort Analysis
9%
Quality of Life
9%
Hearing Impairment
9%
Prevalence
9%
Tretinoin
8%
Adolescent
8%
Fluorodeoxyglucose F 18
8%
Cell Transplantation
8%
Hematopoietic Stem Cell
8%
Medical Intervention
8%
Metastatic Carcinoma
8%
Hazard Ratio
7%
Echocardiography
7%
Ototoxicity
7%
Group Therapy
7%
Oncology
6%
Positron Emission Tomography-Computed Tomography
6%
Cardiomyopathy
6%
Placebo
5%
Cardiology
5%
Emergency Medical Technician
5%
Progression Free Survival
5%
Fluorine-18
5%
(3 Iodobenzyl)guanidine
5%
High Risk Population
5%
Fluorodeoxyglucose
5%
COVID-19
5%
Iodine 131
5%
Immunotherapy
5%
Dexrazoxane
5%
Cardiovascular Disease
5%
Pharmacology, Toxicology and Pharmaceutical Science
Childhood Cancer
71%
Anthracycline
64%
Malignant Neoplasm
36%
Cardiotoxicity
32%
Randomized Controlled Trial
26%
Heart Failure
23%
Neuroblastoma
22%
Chemotherapy
21%
Adverse Event
18%
High Dose Chemotherapy
17%
Overall Survival
17%
Event Free Survival
17%
Ewing Sarcoma
11%
Hearing Impairment
10%
Prevalence
9%
Razoxane
9%
Disease
8%
Anticarcinogen
8%
Progression Free Survival
8%
Retinoic Acid
8%
Doxorubicin
8%
Neoplasm
7%
Cohort Study
7%
Cisplatin
7%
Cyclophosphamide
7%
Ifosfamide
6%
Controlled Clinical Trial
6%
Recurrent Disease
6%
Mitoxantrone
5%
Thyroid Disease
5%
Ototoxicity
5%
